From new approaches in alopecia areata (AA) assessment to emerging agents for hidradenitis suppurativa (HS), catch up on the insights you might have missed at this year’s #EADVCongress with our NEW highlights #MedSky #DermSky #EADV2025

ow.ly/bbzF50X7RSf

Dermatite atopique : des conséquences à long terme, au-delà de la peau Pensées suicidaires, harcèlement, troubles du sommeil… Une étude épidémiologique déclarative montre l’impact à long terme de la dermatite atopique, en dehors des symptômes cutanés.

Dermatite atopique : des conséquences à long terme, au-delà de la peau
Une étude épidémiologique déclarative montre l’impact à long terme de la dermatite atopique, en dehors des symptômes cutanés. (congrès #EADV2025)
ms.spr.ly/63320sLdvK

aGLP-1 et psoriasis : des bénéfices qui vont au-delà des effets sur le contrôle du poids et la glycémie Chez les patients atteints de psoriasis, le traitement du diabète ou de l’obésité par aGLP-1 est associé à une diminution de la mortalité toutes causes confondues, et de certains risques cardiovasculaires et psychiatriques.

aGLP-1 et psoriasis : des bénéfices qui vont au-delà des effets sur le contrôle du poids et la glycémie #EADV2025
ms.spr.ly/63328svijy

GLP-1 Drugs Look Good for Psoriasis, Not So Much for Hair Lower mortality, heart and psychiatric risks in psoriasis, but more evidence of hair loss

GLP-1 agonists appeared to have a bigger impact on the physical and mental health of patients with psoriasis compared with other patients, a large retrospective cohort study showed. #EADV2025
www.medpagetoday.com/meetingcoverage/eadv/117...

EADV 2025: Affibody’s izokibep shows strong Phase III results in HS Phase III trial data presented at EADV 2025 highlight a 75% reduction in abscesses and inflammatory nodules with izokibep in hidradenitis suppurativa (HS).

Affibody’s izokibep delivers positive Phase III results in hidradenitis suppurativa: 37% of patients achieved HiSCR75 at week 16 vs 20% on placebo, with strong pain and QoL improvements.

#News #EADV2025 #HS #Dermatology #ClinicalTrials #hidradenitissuppurativa

EADV 2025: Affibody’s izokibep shows strong Phase III results in HS Phase III trial data presented at EADV 2025 highlight a 75% reduction in abscesses and inflammatory nodules with izokibep in hidradenitis suppurativa (HS).

Affibody’s izokibep delivers positive Phase III results in hidradenitis suppurativa: 37% of patients achieved HiSCR75 at week 16 vs 20% on placebo, with strong pain and QoL improvements.

#News #EADV2025 #HS #Dermatology #ClinicalTrials #hidradenitissuppurativa

What are the key takeaways in #CSU management from #EADVCongress? Catch-up on the updates you need to know, from clinical outcomes in key trials to comparative insights on advanced therapies, with our short summary articles available now #MedSky #EADV2025 #DermSky

ow.ly/P2cf50X0VnN

Atopic Eczema Linked to Suicidal Ideation in Global Study of 30,000 Adults | HCPLive EADV 2025 findings show patients with atopic eczema face greater risks of depression, anxiety, sleep disorders, and stigmatization.

Global study of 30,000+ adults links #AtopicEczema to greater rates of suicidal ideation, depression, anxiety & sleep disorders. Findings highlight the need to address the hidden psychological burden. #EADV2025

New data reveals ritlecitinib's long-term efficacy for #AlopeciaAreata, showing sustained hair regrowth in 30% of patients after 3 years.

Check out our interview with Brett King, MD, of @Yale, from #EADV2025: www.hcplive.com/view/long-te...

'Hit Hard, Hit Early' Psoriasis Treatment Strategy Gains Momentum Earlier therapy produces high rates of skin clearance, prolonged treatment-free intervals

Earlier initiation of biologic therapy for psoriasis led to complete skin clearance sooner and significantly more often as compared with starting later, a new analysis of a randomized trial showed. #EADV2025
www.medpagetoday.com/meetingcoverage/eadv/117...

Congratulations to Johann Gudjonsson who received the EADV International Award at #EADV2025.
We are very grateful to Johann for his invaluable work as a senior editor of the JID!!
Photo credit: Thy Thy Do
#dermsky #dermatology #dermscience #dermresearch #Skinresearch #psoriasis #atopicdermatitis

Patients with psoriasis are at higher risk of age-related macular degeneration — but biologics may cut that risk by 27%, says new #EADV2025 research. Both wet and dry AMD were elevated, with stronger ties to wet AMD.

Read more: ophthalmologymanagem...
#Ophthalmology #Retina #AMD

Once-Daily Pill for Psoriasis Gets High Marks in Multiple Studies Early, durable improvement in skin clearance with novel IL-23 blocker icotrokinra

About 50% more patients with plaque psoriasis had at least 90% skin clearance within 6 months with a novel, once-daily pill as compared with a current standard of care, two randomized trials showed. #EADV2025
www.medpagetoday.com/meetingcoverage/eadv/117...

The third study presented at #EADV2025 from Novartis using spatial transcriptomics to look at #hidradenitis

Some beautiful pictures showing the distribution of fibroblasts, B cells, plasma cells, T cells around a lesion

IMO more data to suggest a need to hit multiple targets

Exciting to hear a new bivalent drug that targets TNF and OX40L Brivekimig for the treatment of #hidradenitis - we likely need more drugs that have multiple targets to treat this difficult disease

Looking forward to the explanatory phase III RCTs

#EADV2025

Probably the closest effort to precision medicine so far in dermatology presented by Michel Gillet - using nanostring measuring gene expression - to differentiate between skin diseases outside of morphology

#EADV2025

That’s it for our round-up of one of the many 'Controversies' sessions at this year’s #EADVCongress. For more insights on AA, visit Medthority now for the updates you need to know #EADV2025 #MedSky #DermSky

ow.ly/nJax50WZh7u

❓Where do you stand on PRP for alopecia areata? Promising frontier or premature hype? Join the conversation in the comments below #EADVCongress #EADV2025 #MedSky #DermSky

The debate reflected a broader tension in dermatology: innovation vs evidence. PRP is biologically plausible and increasingly popular, but is it ready for prime time in AA? #EADVCongress #EADV2025 #MedX #DermSky

Sigall emphasized the importance of standardization: dose, purity, activation, and efficiency of PRP prep all impact outcomes. Without consistency, results can vary widely #EADVCongress #EADV2025 #MedSky #DermSky

Rakowska countered with caution, highlighting:

💵 High costs

❗Procedural risks

📄Lack of support in contemporary guidelines

Plus, she pointed to British guidance favoring established therapies over PRP #EADVCongress #EADV2025 #MedSky #DermSky

Sigall started by arguing in favor of PRP, citing:

🩸Capillary formation

🩸Improved nutrient delivery

🩸Anti-apoptotic effects

These mechanisms may support follicle survival and regrowth in AA #EADVCongress #EADV2025 #MedSky #DermSky

Platelet-rich plasma (PRP) therapy for alopecia areata (AA) remains one of dermatology’s most debated topics. At #EADVCongress, Daniel Asz Sigall and Adriana Rakowska went head-to-head on its merits and limitations. Catch-up on the debate with our thread below #EADV2025 #MedSky #DermSky

If you enjoyed reading through our highlights of the 'Hidradenitis suppurativa' session at #EADVCongress, keep an eye on our #dermatology hub for congress highlights coming soon #EADV2025 #MedSky #DermSky

ow.ly/c8Nv50WYIce

That's a wrap! From phenotypes to pregnancy, comorbidities to combined care — #EADVCongress spotlighted the complexity of HS. Early action, holistic strategies, and patient-centred innovation are shaping the future of HS care #EADV2025 #MedSky #Dermatology #DermSky

What does the future hold for HS management? Emerging therapies like GLP-1 analogues and microbiome modulations show promise in easing the burden of disease in women #EADVCongress #EADV2025 #MedSky #Dermatology #DermSky

🤰With a diagnostic delay of ~7 years and impacts on pregnancy and childbirth, Ganceviciene called for improvements to diagnosis in women and a tailored approach to HS care at #EADVCongress #EADV2025 #MedSky #Dermatology #DermSky

👩How does HS affect women? Ruta Ganceviciene shared how differences in the skin microbiome between men and women may help explain the disparity in HS prevalence #EADVCongress #EADV2025 #MedSky #Dermatology #DermSky

“You have to remove it completely to stop it coming back.” Villani highlighted the critical role of surgical intervention in HS management and advocated for a combined approach: biologics, surgery, and holistic care #EADVCongress #EADV2025 #MedSky #Dermatology #DermSky

🕰️“Early matters.” Alex Villani stressed the importance of early intervention and a holistic approach to modify disease progression in HS. Weight loss, smoking cessation, reduced friction, microbiome care, and stress management can all play a role #EADVCongress #EADV2025 #MedSky #Dermatology